The Impact of Remimazolam on the Safety and Effectiveness of Electroconvulsive Therapy in Patients with Mental Disorders

A Study on the Efficacy and Safety of Remimazolam in Electroconvulsive Therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114332

Enrollment

Unknown

Registered

2025-12-10

Start date

2026-01-01

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental Disorders

Interventions

Remimazolam:Remimazolam anesthesia induction

Propofol:Propofol anesthesia induction

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with mental disorders and undergoing ECT treatment in our hospital; 2. Aged 18 - 65 years; 3. The patient or their guardian has signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to remimazolam or propofol. 2. Patients who refuse electroconvulsive therapy.

Design outcomes

Primary

Measure	Time frame
EEG suizure duration;Hypotension;Injection pain;	—

Secondary

Measure	Time frame
Postictal Suppression Index;Average Seizure Energy Index;Maximum Sustained Power;Time to Peak Power;Induction time;Recovery time;Dizziness;Nausea and vomiting;	—

Countries

China

Contacts

Public ContactTianqi Shen

The 984th Hospital of the Joint Logistics Support Force

anaesthe984@aliyun.com+86 176 0020 5162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 24, 2026